Giovanni Caforio, Bristol Myers Squibb CEO (The Galien Foundation)

Bris­tol My­ers makes a $4.8B bet on KRAS, strik­ing deal to ac­quire Mi­rati

Bris­tol My­ers Squibb has signed a $4.8 bil­lion deal to buy Mi­rati Ther­a­peu­tics and its can­cer drug Kraza­ti, which tar­gets what …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.